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Background: Optimal adherence to antiretroviral therapy is critical to prevent HIV drug resistance (HIVDR)
epidemic. The objective of the study was to investigate the best performing adherence assessment method for
predicting virological failure in resource-limited settings (RLS).
Method: This study was a single-centre prospective cohort, enrolling 220 HIV-infected adult patients attending
an HIV/AIDS Care and Treatment Centre in Dar es Salaam, Tanzania, in 2010. Pharmacy refill, self-report
(via visual analog scale [VAS] and the Swiss HIV Cohort study-adherence questionnaire), pill count, and appointment
keeping adherence measurements were taken.
Univariate logistic regression (LR) was done to explore a cut-off that gives a better trade-off between sensitivity and
specificity, and a higher area under the curve (AUC) based on receiver operating characteristic curve in predicting
virological failure. Additionally, the adherence models were evaluated by fitting multivariate LR with stepwise functions,
decision trees, and random forests models, assessing 10-fold multiple cross validation (MCV). Patient factors associated
with virological failure were determined using LR.
Results: Viral load measurements at baseline and one year after recruitment were available for 162 patients, of whom
55 (34%) had detectable viral load and 17 (10.5%) had immunological failure at one year after recruitment. The optimal
cut-off points significantly predictive of virological failure were 95%, 80%, 95% and 90% for VAS, appointment keeping,
pharmacy refill, and pill count adherence respectively. The AUC for these methods ranged from 0.52 to 0.61,
with pharmacy refill giving the best performance at AUC 0.61.
Multivariate logistic regression with boost stepwise MCV had higher AUC (0.64) compared to all univariate
adherence models, except pharmacy refill adherence univariate model, which was comparable to the multivariate
model (AUC = 0.64). Decision trees and random forests models were inferior to boost stepwise model.
Pharmacy refill adherence (<95%) emerged as the best method for predicting virological failure. Other significant
predictors in multivariate LR were having a baseline CD4 T lymphocytes count < 200 cells/μl, being unable to recall the
diagnosis date, and a higher weight.
Conclusion: Pharmacy refill has the potential to predict virological failure and to identify patients to be considered for
viral load monitoring and HIVDR testing in RLS.
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Widespread antiretroviral scale-up programs are taking
place in resource-limited settings (RLS) [1]. Where re-
sources are available, monitoring response to combination
antiretroviral therapy (ART) by virological outcome is
recommended because of its strong correlation with
therapy success in HIV patients. At virological failure,
therapy changes are then guided by genotypic resistance
testing. However, sophisticated laboratory tests, such as
virological monitoring and genotyping, are very expensive
and not used in RLS [1-3]. Therefore, in RLS, clinical or
immunological criteria are used to evaluate ART outcome.
It has been shown that relying on such clinical and im-
munological criteria to change therapy can cause high
levels of HIV drug resistance (HIVDR), compromising
the next line of therapy [2,3]. It is, therefore, important to
identify affordable proxy markers for response to therapy in
RLS. There is sufficient international evidence to support
that adherence to combination ART is a major predictor of
viral suppression [4,5], HIVDR [6,7], CD4 T lymphocytes
count recovery [8] and survival [5,8,9].
Strategies to measure adherence to ART include the
Medication Event Monitoring System (MEMS), pharmacy
refill records, pill count, appointment keeping, adherence
diaries, and interviewer-administered or self-report ques-
tionnaires [10-13]. Current objective methods of measuring
adherence include MEMS, biologic measures, and pill
counts [14,15]. Each of these assessment methods is as-
sociated with certain strengths and drawbacks. MEMS
is widely used in clinical studies, whereas pill count,
self-report, and pharmacy refill are widely used in the
context of HIV and AIDS clinical-care settings.
Self-report utilizing structured questionnaires is popular
in RLS, due to its ease of use in busy settings, affordability,
and low staff requirements. Self-report has consistently
been correlated with viral load response to therapy and
has been proposed as a robust and appropriate indicator
of adherence [16,17]. However, other documented studies
showed that self-reports have low sensitivity and positive
predictive value [18]. While self-reported adherence may
be consistently correlated with important clinical outcomes,
these relationships are generally modest at best, and
the method continues to lack accuracy and precision.
Self-reported adherence is known to overestimate ad-
herence, due to recall bias and social desirability. Fur-
thermore, the inaccuracy of self-reports is highlighted
by the need to often dichotomize the highly-skewed
data with cut-off points of 90 – 100% in most adher-
ence analyses [17]. A combination of adherence strat-
egies is recommended to improve the accuracy of this
measurement [18].
In sub-Saharan Africa, adherence to ART has been
touted to be equal to or even higher than levels in resource-
rich settings (RRS) [19]. However, many adherence studiesare based on non-objective self-report measurements and
are not well validated against viral load measurement
[20]. Therefore, it is still arguable whether these higher
adherence reports reflect the actual situation. More-
over, treatment failures have been shown, even with
self-reported high adherence [21]. It is important to
acknowledge that self-reported adherence measures
are far from robust. Its wide use and acceptance need
further justification than the few selected studies that
show correlation between this measure with other object-
ive measures and with virological, clinical immunological,
and survival outcome [16].
Pill count and appointment keeping adherence are among
the early warning indicators (EWIs) recommended by the
World Health Organization (WHO) as surrogate markers
for emergence of HIVDR [22]. Manual pill count is a cheap
and easy alternative to estimate dosages taken. However, it
is limited by the intensive need of staff and the possibility of
pill sharing or dumping by the patients. Appointment keep-
ing can be easily abstracted from attendance records, but is
only a subjective measure.
Another objective method that has higher potential is
pharmacy refill adherence, which is commonly obtained
in clinical care. It has been validated as a measure of ART
adherence related to viral load [10]. Although pharmacy
refill method is not constrained by the recall bias seen
with self-report, its utility for predicting patient outcomes
is poorly validated in RLS [23,24].
Apparently, there is no single consensus tool to cap-
ture adherence to ART and no accepted gold standard
to assess adherence especially in RLS [14,15,25,26].
Moreover, studies show low or moderate correlation
among methods, which can be attributed to the fact
that they measure separate dimensions of adherence
behaviour, that different non-adherence cut-off points
have been established, or even to the limitations of the
methods themselves. These issues result in varied
non-adherence frequency measures throughout time
and among diverse settings.
Validating adherence measurement against viral load
is of utmost importance. An accurate and sensitive
measure of adherence should give clinicians objective
data to use during discussions on individuals’ non-
adherence risk factors without causing shame or
stigma to a patient [27]. The fear of stigma is a prob-
lem in non-adherence disclosure and can lead to over-
reporting of adherence. The objective of the current
study was to validate an instrument capable of measur-
ing adherence to ART in HIV-infected adults by evalu-
ating how such measurements can be used to predict
virological outcome in Tanzania. Such an instrument
can be used to select patients for viral load measure-
ment and HIVDR testing, as a lower-cost alternative to
generalized viral load follow-up.
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Study design
This was a single-centre prospective cohort study enrolling
HIV-infected adult patients attending an HIV/AIDS Care
and Treatment Centre (CTC) that provides ART at Amana
District Hospital in Dar es Salaam, Tanzania, in 2010.
Patients on ART are normally scheduled to return for
antiretroviral (ARV) pick-ups at least once per month.
During the visit, they also consult with the clinician
after receiving adherence counselling from the nurses.
CD4 T lymphocytes count measurements are taken at
least once every six months. Two hundred and fifty-four
patients were invited into the study during the months
of May to July, 2010. Selection criteria were either start-
ing ART or being on ART. Patients were conveniently
sampled, as the study researcher continuously recruited
patients who were referred by nurse counsellors, the
first contacts at the clinic. Each day, 10-15 unselected
patients were recruited into the study. Exclusion criteria
were being younger than 18 years of age, pregnant, having
opportunistic infections, or malignancy. Of the 254 patients
recruited into the study, 34 (13.4%) were excluded from
analysis for various reasons (see Figure 1). The remaining
220 provided adherence information and were followed for
a period of one year. The herein presented study included
162 patients who completed a one-year follow-up and had
their adherence, immunological, and virological outcome
monitored over the entire period.
Ethical issue
Issues pertaining to patient confidentiality, benefits and
risks to participating patients, justice, rights and respect
that the patients deserve were addressed by ethical clearanceFigure 1 Patients sampling flowchart.and informed consent. The study was approved by the
Muhimbili University of Health and Allied Sciences
(MUHAS) Research Ethics Committee. Only patients
who were willing to participate in the study and who
signed an informed consent were recruited into this
study. Patient codes were used to de-link the patient
data in databases. Patients did not receive any payments
to motivate them to participate in the study.
Virological and immunological outcomes
Virological and immunological outcomes were assessed at
the one-year follow-up. These outcomes were dichotomized
according to the following definitions: Virological failure
was defined as having a viral load above the detection limit
of 400 copies/mL; and immunological failure was defined
according to the WHO guidelines as having (i) a CD4 T
lymphocytes count of 100 cells/μl at six months post ART,
(ii) a CD4 T lymphocytes count of equal to or less than
CD4 pre-ART at six months on ART, or (iii) 50% reduction
from the on-ART peak CD4 T lymphocytes count [28,29].
Adherence measurement
Adherence was measured using pharmacy refill, self-report,
pill count, and appointment keeping methods, as described
for each method. Adherences measurements were taken at
four time points during a one-year follow-up, including at
recruitment (zero), one, two, and 12 months after recruit-
ment. Overall adherence for each method was the mean of
the measurements taken at the four time points and this
mean was considered in subsequent analyses.
Pharmacy refill
Each refill period was identified as the interval between
the last visit date and the scheduled refill date. Refill adher-
ence was 100% if all pills during the scheduled refill period
had been picked up on time. Refill percent values above
100 for patients who refilled earlier than scheduled were
rounded to 100 percent. Refill adherence was not calculated
on a monthly basis to reduce an error of a few additional
pills left over at the end of each refill period. The calcula-
tion was based on cumulative sum of the days that a patient
was late for ARV pick-up appointments in each month over
the year, divided by the total number of days over all pe-
riods between pick-up periods in the year of study, resulting
in the percentage of time the patient was without medica-
tion over the whole year.
Self-report
The researcher for this study administered a self-report
questionnaire to patients to assess missed dosages over
the previous one month. During a one-year follow-up,
self-report was used to determine adherence at recruitment
(zero), one, two, and 12 months after recruitment. For pa-
tients who started ART at recruitment, the measurement at
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ence was investigated using a validated study tool [26]. This
validated study tool consists of two major sections: 1) the
visual analog scale (VAS), which probed the percentage of
doses taken in the previous month; and 2) it probes two
questions from the Swiss HIV Cohort Study Adherence
Questionnaire (SHCS-AQ) regarding frequency of missed
doses and if a patient ever missed two consecutive doses
(drug holiday) in the previous month. By definition,
reporting of having missed at least one ARV dose or
two consecutive doses in the month preceding the
interview was scored as non-adherent [26,30].
Pill count
At each visit, pills remaining in bottles were counted and
the proportion of these pills to the dispensed pills during
the previous visit was calculated based on the dose and
the number of days dispensed. The pill count adherence
percent was obtained by dividing the number of pills con-
sumed by the total number of pills at the beginning of the
given interval and multiplied by 100.
Appointment keeping
At this CTC, appointments were issued based on the
period that the dispensed ARV stock would last, which
usually this amounts to one month. Appointment keep-
ing was deduced from the medical records and database.
A patient visiting on the scheduled appointment was
scored as 100% appointment adherent, whereas if an
appointment was skipped entirely, it was scored as 0%
adherence. For a delayed appointment, the proportions
of days late (in% with respect to the total number of
days between two visits) were subtracted from 100.
Statistical analyses
Univariate analysis was done to explore a cut-off that
gives a better trade-off between sensitivity and specificity,
and a higher area under the curve (AUC), based on re-
ceiver operating characteristic (ROC) curve in predicting
virological failure. For each method, we used a threshold
cut-off beginning with 100% and decreasing to 50% in
steps of 5. At the selected cut-off for pharmacy refill, VAS,
pill count, and appointment keeping (a binary variable-
expressed adherence, such that patients with adherence
below the cut-off were classified as non-adherent, whereas
the others were classified as adherent). The trade-off for
sensitivity and specificity was analysed upon changing the
adherence cut-off to predict virological failure at 12 months,
which was dichotomized using two different viral load
cut-off points: > 400 copies/mL or > 1,000 copies/mL.
The 400 copies/ml virological cut-off was the detection
limit of this study’s viral load measurement, while 1,000
represented a virologic cut-off widely used to perform
genotyping. A model was also tested combining adherenceand immunological outcome to predict virological failure.
The performance criteria for all adherence measures
were calculated with two-by-two tables and ROC ana-
lysis. Univariate logistic regression (LR) was used to de-
termine patient baseline factors associated with virological
outcome. Also, evaluation of the adherence models was
done by fitting multivariate LR with stepwise functions
(Akaike information criterion [AIC] and boost), decision
trees, and random forests assessing extra-sample error
via multiple 10-fold cross validation (MCV), repeated 50
times with random seeds. All models were analysed in
terms of different performance (goodness-of-fit functions),
specifically AUC, accuracy, true positive rate (sensitivity),
and true negative rate (specificity). Performance distri-
butions were compared pair-wise with a t-test adjusted
for sample overlap (due to the MCV procedure) and
multiple comparisons.
Kaplan Meier survival analysis was used to determine
the difference between the time taken to increase the
CD4 T lymphocytes count by 50 cells/μl or by 100 cells/μl
between adherent and non-adherent patients. Furthermore,
Cox regression analysis was done to adjust for confounding
factors such as age, gender, and CD4 T lymphocytes count
at baseline. Descriptive analyses, including median inter-
quartile range (IQR) for numerical variables, frequencies,
and proportions for categorical variables, and tested
for association using Fisher and Chi-square tests for
categorical variables, and Wilcoxon signed rank test
for continuous values. The level of significance for all
analyses was p < 0.05. All statistical analyses were per-
formed using the R statistical package version 2.15.1
[31] and Weka open source software [32].
Results
Cohort information
A total of 162 (73.6%) out of the 220 patients followed for
a one-year period had a virological outcome, an immuno-
logical outcome, and adherence data at the one-year time
point and were included in this study (see Figure 1). The
median IQR follow-up duration was 13 (11 - 13) months.
Of the 220 patients, 49 (22.3%) were excluded because
they could not be interviewed at the one-year follow-up.
Four (1.8%) had died before the one-year end point; eight
(3.6%) were transferred to other centres; 20 (9.1%) visited
in the last month, but could not meet the interviewer; and
17 (7.7%) were likely to be lost to follow-up, as they had
missed their appointments for at least three months. An
additional nine (4.1%) patients were excluded from the
study, due to lack of viral load measurement. There was
no significant difference in terms of socio-demographic
and social support characteristics, adherence measured by
different methods, and immunological status between in-
cluded and excluded patients (see Additional file 1). They
also did not differ in duration of therapy or support for
Sangeda et al. BMC Public Health 2014, 14:1035 Page 5 of 11
http://www.biomedcentral.com/1471-2458/14/1035treatment. However, included patients were more likely to
receive atripla or a once-daily single tablet regimen than
the excluded group, while other therapy regimen distribu-
tion was not different. Also, included patients had a CD4
T lymphocytes count measurement performed significantly
more often than the excluded group; eight (6 - 11) times
compared to seven (4 - 11) times (p = 0.03).
Among the patients included in the study, the median
IQR of ART exposure by the end of the observation
period was 37 (30 - 48) months. This information was
only available for patients with follow-up. With regard
to duration of therapy at recruitment, there was no sig-
nificance difference between included and excluded
patients (p = 0.36).
Performance of adherence models
With regard to adherence measurements, performance for
various cut-off points to predict a viral load above 400 or
above 1,000 copies/ml is shown in Table 1, Additional file 2,
and Additional file 3. The 400 copies/ml virological cut-off
was the study’s detection limit of viral load measurement,
while 1,000 represents virologic cut-off widely used to
perform genotyping. For SHCS-AQ, there are no cut-off
points, as non-adherence is defined as in the methods.
Evaluation of prediction by adherence measurements
taken at different time points of follow-up and by over-
all adherence was similar (see Additional file 3). For the
remainder of this paper, only overall adherence is con-
sidered. Prediction performance was better when pre-
dicting a viral load above 1,000 copies/ml (compared to
above 400 copies/ml; see Additional file 2), but this viral
load was not the clinically relevant one and was not ana-
lysed further. The optimal trade-off between highest AUC,
acceptable sensitivity and specificity, and still being signifi-
cantly predictive for virological failure (VL > 400 copies/ml)
was 95%, 80%, 95% and 90% for VAS, appointment keeping,
pharmacy refill, and pill count adherence respectively
(see Table 1). At these adherence cut-off values, the
proportion of adherent patients were 87.0%, 78.9%,
24.5%, and 54.3% for VAS, appointment keeping, pill count,
and pharmacy refill adherence respectively. Whereas,
for SHCS-AQ 71.6% of patients were adherent. For VAS,Table 1 Values of sensitivity, specificity, and ROC area under
Adherence
Adherence method % cut-off AUC Accuracy p-value
SHCS-AQ NA 0.52 58.64 0.33
VAS 95 0.53 64.20 <0.0001
Appointment keeping 80 0.53 62.11 0.01
Pharmacy refill 95 0.61 61.11 0.02
Pill count 90 0.53 44.03 <0.0001
Key: SHCS-AQ = Swiss HIV Cohort Study Adherence Questionnaire;
VAS = Visual Analog Scale; AUC = Area under the Curve; ROC = Receiver Operating Cappointment keeping, pharmacy refill, and pill count
adherence, the median IQR was 100 (98.33 - 100), 100
(84.33 - 100), 89.55 (86.23 - 100), and 78.83 (74.04 - 89.90)
respectively. Combining adherence and immunological
outcome improved the accuracy and sensitivity to pre-
dict virological failure, while specificity was not much
worse (see Table 1).
Factors significantly associated with virological and
immunological outcome
At recruitment, 13% of patients who were on treatment
for more than four months had detectable viral load. This
rate increased to 34% of all patients after the one-year
follow-up. Two of 15 patients who started ART at recruit-
ment still had a detectable viral load after one year. The
odds of virological failure for various predictors are shown
in Table 2. Patients who had a detectable viral load did
not differ significantly from those with an undetectable
viral load in terms of socio-demographic characteristics,
except with respect to distance travelled to the centre:
those with undetectable viral load lived closer, six (2 - 8)
km as compared to seven (4.5 - 8.5) km in the subset with
detectable viral load (p = 0.04). Patients with detectable
viral load were more significantly taking triomune, a fixed
combination of stavudine, lamivudine, and nevirapine,
than those with undetectable viral load (p = 0.05). Detect-
able viral load at study entry, immunological failure at one
year, and poor pharmacy refill adherence were other
significant predictors of detectable viral load at the end
of the study. Having a drug holiday and baseline CD4
T lymphocytes count had a borderline significance trend
(see Additional file 4). The median IQR CD4 T lympho-
cytes count at last visit was 379 (255 - 541) cells/μl.
Twenty-eight (17.3%) patients had CD4 T lymphocytes
count less than 200 cells/μl.
In univariate LR analysis, odds of virological failure
were determined. The study suggests that, being able to
recall the diagnosis date, being on an efavirenz-containing
regimen, having a pharmacy refill adherence of > 95% and
having an undetectable viral load at baseline were signifi-
cantly associated with lower likelihood of virological failure.
On the contrary, having a baseline CD4 T lymphocytesthe curve (AUC) by adherence assessment method
Adherence + immunological outcome
Sen Spe AUC Accuracy p-value Sen Spe
0.31 0.73 0.52 56.79 0.90 0.38 0.66
0.16 0.89 0.56 64.81 <0.01 0.27 0.84
0.25 0.81 0.59 64.60 0.43 0.42 0.76
0.60 0.62 0.63 61.11 <0.0001 0.69 0.57
0.79 0.26 0.53 44.10 <0.0001 0.82 0.25
haracteristic; Sen = Sensitivity; Spe = Specificity; NA = not applicable.
Table 2 Predictors of one year of follow-up virological and immunological failure by univariate logistic regression
Virological failure Immunological failure
> 400 copies/ml > 1,000 copies/ml
Predictor OR (95% CI) p-value OR (95% CI) p-value OR ( 95% CI) p-value
Age per 1 year older 1 (0.96 - 1.03) 0.8 0.97 (0.93 - 1.02) 0.24 0.92 (0.85 - 0.98) 0.02
Being able to recall diagnosis date 0.39 (0.2 - 0.75) 0.01 0.3 (0.14 - 0.63) <0.01 0.31(0.1 - 0.87) 0.03
Being on nevirapine regimen 2.17 (1.06 - 4.64) 0.04 2.76 (1.18 - 7.28) 0.03 1.3 (0.46 - 4.28) 0.64
Being on efavirenz regimen 0.48 (0.22 - 0.98) 0.05 0.37 (0.14 - 0.88) 0.03 0.79 (0.24 - 2.27) 0.68
Being on stavudine regimen 1.99 (1.03 - 3.89) 0.04 2.23 (1.06 - 4.83) 0.04 1.71 (0.62 - 4.94) 0.3
Body mass index per unit 1.06 (1.01 - 1.12) 0.03 1.02 (0.96 - 1.07) 0.53 0.97 (0.87 - 1.05) 0.5
Weight per 1 kg higher 1.03 (1 - 1.06) 0.03 1.02 (0.99 - 1.05) 0.13 0.99 (0.95 - 1.03) 0.65
Having baseline CD4 T lymphocytes count < 200 cell/μl 1.47 (0.7 - 3.03) 0.3 2.9 (1.32 - 6.35) 0.01 2.9 (1.02 - 8.17) 0.04
Therapy duration 8.67 (1.47 - 66.9) 0.02 8.75 (1.35 - 80.87) 0.03 2 (0.2 - 19.79) 0.53
Being on triomune regimen 2.07 (1.07 - 4.04) 0.03 2.31 (1.1 - 5) 0.03 1.76 (0.64 - 5.08) 0.28
Undetectable viral load at baseline 0.46 (0.21 - 1.01) 0.05 0.29 (0.13 - 0.68) <0.01 0.23 (0.08 - 0.68) 0.01
Ever having drug holidays 3.32 (1.06 - 11.29) 0.04 5.2 (1.56 - 18.4) 0.01 2.46 (0.54 - 10.72) 0.23
SHCS-AQ adherence 0.83 (0.41 - 1.72) 0.61 0.78 (0.36 - 1.76) 0.54 0.7 (0.25 - 2.14) 0.51
VAS adherence (>95%) 0.65 (0.25 - 1.68) 0.36 0.54 (0.2 - 1.53) 0.22 0.21 (0.07 - 0.69) 0.01
Appointment adherence >80%) 0.68 (0.31 - 1.5) 0.33 0.65 (0.28 - 1.57) 0.32 1.28 (0.39 - 5.8) 0.71
Pharmacy refill adherence (>95%) 0.41 (0.21 - 0.8) 0.01 0.26 (0.12 - 0.57) <0.01 1.23 (0.45 - 3.55) 0.69
Pill count adherence (>90%) 1.86 (0.62 - 5.5) 0.26 1.9 (0.56 - 5.78) 0.27 0.66 (0.04 - 3.7) 0.7
Key: SHCS-AQ = Swiss HIV Cohort study Adherence questionnaire; VAS = Visual analog scale; OR = odds ratio; CI = confidence interval.
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pine, or stavudine regimen, having a higher body weight or
body mass index (BMI), longer therapy duration, and hav-
ing drug holidays were predictors of poor virological out-
come (see Table 2). Adherence measured by the self-report
methods VAS (>95%) and SHCS-AQ, appointment keeping
(>80%) and pill count (>90%) (each time the optimum%
cut-off was from Table 1) were not predictive of virological
outcome. Older age, undetectable viral load at baseline, and
VAS adherence were associated with lower likelihood of
immunological failure, whereas having a baseline CD4 T
lymphocytes count of less than 200 cells/μl was associated
with immunological failure. According to the WHO defin-
ition of immunological failure, 17 of 162 (10.5%) patients
had immunological failure at one year after recruitment.
Pharmacy refill was the only adherence measurement
that was significantly associated with 12-month virological
outcome (see Table 2 and Table 3). The proportion of pa-
tients with undetectable viral load increased with increasing
pharmacy refill adherence, and was highest in patients with
over 95% adherence (see Figure 2). Moreover, patients with
detectable viral load had significantly lower pharmacy refill
adherence with 91.9% (80 - 99.4%), as compared to 98.8%
(91.1 – 100%) in patients with undetectable viral load
(p = 0. 003). Of the 17 patients with immunological failure,
10 had a pharmacy refill adherence of > 95%.
The sensitivity results indicated that the pharmacy refill
adherence has the highest AUC and best balance betweensensitivity and specificity, as compared with other adher-
ence measurements (see Table 1 and Additional file 5). At
a cut-off of 95%, refill adherence covers the highest AUC
in the ROC curve and significantly predicts virological
failure. The proportion decreased in a dose response
fashion in lower adherence cut-off groups (see Figure 2).
Increasing adherence was associated with increased
rates of undetectable viral load.
Multiple cross validation models to predict virological failure
Fifty independent runs of 10-fold MCV were executed,
using different input sets and feature selection methods
(see Table 4 and Additional file 6). MCV univariate models
using a dichotomized adherence variable gave AUC and ac-
curacy that were not much different than the univariate
evaluation in Table 1 and Additional file 3, although sensi-
tivity was consistently lower. A univariate logistic regression
fitted on actual numeric (instead of optimized cut-off )
pharmacy refill adherence yielded an AUC of 0.64 and
accuracy of 68.73 (see Additional file 6). This was
slightly better than with the optimal cut-off analysis
shown in Table 1, but sensitivity was worse. A full LR
model combining all variables in boost stepwise gave
AUC of 0.64, which was higher than all the univariate
adherence models, except the pharmacy refill adher-
ence using continuous numeric values. The non-linear
methods (decision trees and random forests) did not
show improvement over the LR (see Table 4).
Table 3 Independent predictors of virological and immunological failure
> 400 copies/ml >1,000 copies/ml Immunological failure
Predictor AOR (95% CI) p-value AOR (95% CI) p-value AOR (95% CI) p-value
Pharmacy refill adherence 0.45 (0.21 - 0.92) 0.03 0.24 (0.09 - 0.59) <0.01 0.19 (0.04 - 0.81) 0.02
Being on triomune regimen 2.39 (1.16 - 5.07) 0.02 3.32 (1.36 - 8.64) 0.01 2.09 (0.66 - 7.07) 0.22
Having baseline CD4 T lymphocytes count < 200 cell/μl 1.59 (0.65 - 3.93) 0.31 3.91 (1.38 - 11.59) 0.01 2.05 (0.58 - 7.01) 0.25
Having baseline undetectable viral load 0.33 (0.12 - 0.87) 0.03 0.23 (0.07 - 0.7) 0.01 0.37 (0.1 - 1.35) 0.13
Being able to remember diagnosis date 0.36 (0.17 - 0.75) 0.01 0.23 (0.09 - 0.57) <0.01 0.27 (0.07 - 0.84) 0.03
Age per 1 year older 1.01 (0.97 - 1.05) 0.71 1 (0.95 - 1.05) 0.94 0.97 (0.89 - 1.04) 0.37
Weight per 1 kg higher 1.05 (1.01 - 1.08) 0.01 1.05 (1.01 - 1.1) 0.01 0.99 (0.94 - 1.04) 0.65
Key: AOR (CI) = Adjusted odds ratio (confidence interval).
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ence of < 95%, having a baseline CD4 T lymphocytes
count < 200 cells/μl, being unable to recall the diagnosis
date, and weight per 1 kg higher remained significant in
predicting virological failure (see Table 3). Only phar-
macy refill adherence and being able to recall diagnosis
were significant predictors of immunological outcome.<70 70−79 80−95 >95
Pharmacy refill adherence (%)
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Figure 2 Virological outcome in association with different
pharmacy refill adherence rates. Lowest viral load detection limit
was 400 copies/ml.Kaplan-Meier and Cox model for immunological recovery
Kaplan Meier survival and Cox regression analysis was
performed with months as the time unit, in order to assess
the time taken by patients to recover CD4 T lymphocytes
count by at least 50 or 100 cells/μl (see Figure 3). Patients
who had a pharmacy refill adherence of < 95% recovered
50 and 100 cells/μl in a median (95% confidence interval)
of five (4 - 8) and eight (5 - 10) weeks respectively.
Whereas, patients who were > 95% refill adherent recovered
in 4.5 (4 - 6) and seven (6 - 9) weeks respectively. Although
the median time to reach the increment was longer in the
non-adherent group, this difference did not reach signifi-
cance (log rank p = 0.15 and 0.23 for increment of 50 and
100 cells/μl respectively). However, when pharmacy refill
adherence was combined with age, gender, and CD4 T lym-
phocytes count at baseline, a Cox regression analysis re-
sulted in significant differences (Wald test p < 0.01).
Discussion
The aims of this study were to evaluate the correlation
and validation of adherence with virological outcome
in RLS. In RLS, viral load monitoring, the preferred
method for evaluating treatment outcome, is hindered
by financial and technical constraints, and the widely-
used indicators of response to therapy, as well as clinical
and immunological outcome monitoring, are confounded
by poor sensitivity. The best measurement of adherence,
along with other affordable and easily-obtained variables,
could be used in RLS as a proxy for virological failure.
The best model using such variables to predict virological
failure may be useful to flag patients for viral load mea-
surements, as a cheaper alternative than universal viral
load follow-up. This study was carried out as an explora-
tory study using convenient sampling, and can, therefore,
serve to inform larger studies on pharmacy refill adher-
ence as a predictor of virological treatment response.
Four measures of adherence used in a RLS were vali-
dated against a one-year virological response as a “gold
standard”. Although it is widely agreed that adherence
plays an important role in the ART outcome, there is no
Table 4 Performance of full variable model against the null models using over 10-fold cross validation repeated
50 times to predict virological failure
Model Goodness-of-fit [avg (st.dev)] with respect to failure
Area under roc Accuracy Sensitivity Specificity
Majority class (null model) 0.50 (0.00) 66.07 (2.79) 0.00 (0.00) 1.00 (0.00)
LR on all variables with AIC stepwise 0.62 (0.14) 66.79 (10.10) 0.37 (0.20) 0.82 (0.12)
LR on all variables with boost stepwise 0.64 (0.14) 67.77 (9.82) 0.39 (0.20) 0.83 (0.11)
Random Forest on all variables 0.59 (0.15) 67.80 (9.11) 0.28 (0.19) 0.88 (0.10)
Decision tree on all variables 0.55 (0.12) 65.72 (8.46) 0.21 (0.21) 0.89 (0.13)
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RLS. Each adherent measurement method has inherent
weaknesses in various settings.
There was a high proportion of patients with virological
failure (34%) in the study, despite high self-reporting ad-
herence of > 95% in up to 87% of patients. Factors signifi-
cantly associated with virological failure at the one-year of
follow-up were having pharmacy refill adherence of < 95%,
having baseline CD4 T lymphocytes count < 200 cells/μl,
being on triomune-, stavudine-, or nevirapine-containing
regimen, not being able to recall HIV diagnosis date, a
unit increase in body weight even after correcting for age,
and a baseline viral load. The association between the uses
of triomune may be related to the negative correlation of
both stavudine and nevirapine individually, rather than
the fixed-dose therapy itself. These two drug components0 10 20 30 40 50 60
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Figure 3 Kaplan Meier survival curves showing the time to recover im
adherence cut-off of 95%.are both independently associated with virological failure
after one year of therapy.
Of the adherence measurements, only pharmacy refill
adherence was positively correlated with the virological
response in a dose response relationship per each increas-
ing adherence rate stratified category. The dose response
relationship between pharmacy refill adherence and viro-
logical outcome has also been observed in previous studies
[10,23,33]. Increasing the virological failure threshold to a
viral load > 1,000 copies/mL led to an increase of sensitivity
and specificity, confirming previous observation [34]. While
this is to be expected, given that lack of adherence will
result in lack of virus control, the more relevant clin-
ical cut-off remains the lower cut-off of 400 copies/ml,
which was more related to residual replication of partially-
resistant virus under drug selective pressure. Similar factors0 10 20 30 40 50 60
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munologically by 50 or 100 cells/μL at pharmacy refill at
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http://www.biomedcentral.com/1471-2458/14/1035predicted the immunological outcome. The correlation
of pharmacy refill adherence and virological outcome
has been shown previously [35]. Moreover, pharmacy
refill showed a promising applicability, given its high
performance in multiple validation regression models,
balanced sensitivity and specificity compared to self-
reports, appointment keeping, or pill count methods.
Superiority of pharmacy refill adherence over self-report
has been shown in a number of studies in RRS [10,33,36]
and RLS [23,37]. Generally, lower sensitivity and higher
specificity values were noted for adherence measurement
to predict virological failure, as compared to predicting
virological success. This indicates that adherence meas-
urement is more likely to detect adherent persons who
are likely to have a good virologic outcome, as compared
to identifying failing patients. Combining all variables in a
multiple cross validation-full logistic regression model did
not improve much over the pharmacy refill univariate
model. The non-linear models test for interactions among
variables, and especially random forests perform better if
the variables are interdependent. Since the linear regres-
sion model performed better than the non-linear models,
this indicates that the variables analysed are behaving inde-
pendently with respect to the outcome. Thus, the power of
pharmacy refill to predict virological failure is independent
of other patient variables.
Even though in this study the optimal cut-off for
pharmacy refill was 95%, the dose response relation-
ship shown in the comparison of virological outcome
and grouped pharmacy refill adherence suggests that
ARV regimens suppress viral load even at moderate
adherence of > 70%. This may be related to current reg-
imens that are more potent, and, thus, may sufficiently
sustain complete viral suppression and avoid HIVDR,
especially among patients initiating ART [7,17,38].
Pharmacy refill adherence measurement has a potential
to be used in RLS [24,39]. In most RLS undertaking
special ART scale-up programs, patients receiving free
ARV supplies are obliged to return to the same centre
on a monthly basis to obtain their medication refills,
which allows implementation of this method. Furthermore,
where the pharmacies have a computerized database, the
pharmacy refill adherence measurement becomes feasible,
practical, and guaranteed [39].
There are some limitations to the application of phar-
macy refill adherence. First is the assumption that the
drugs refilled are always consumed. There is no way to
tell if the patient sold, shared, or dumped the medica-
tions after a refill. For that matter, this method is a mere
proxy for adherence. A second drawback is inability to
detect or predict all patients with viral rebound, given
the relatively-low sensitivity for predicting virological
failure (around 60%). Moreover, with this method, it is
not possible to discriminate patterns of adherence, suchas treatment interruption, which may be more risky for
non-nucleoside reverse transcriptase inhibitor resistance
than a run of occasionally missed doses [6,40]. An additional
drawback is when an individual can acquire medication
refills from multiple pharmacies outside the regular clinic.
However, in most RLS, patients have to return to the same
clinic for their monthly ARV refills [7], and, thus, pharmacy
refill is a feasible adherence measurement.
In this study, self-report measures did not predict viro-
logical outcome. Self-reported adherence has not been
consistently validated in RLS [23]. In some studies that
evaluated self-report, it was found to be less sensitive
[37,41]. The unreliable nature of self-report stems from
participants’ beliefs and fears about how the information
provided to clinicians or adherence counsellors would be
used. Thus, accuracy of self-reported adherence may be
undermined if patients fear that reporting non-adherence
could have negative consequences in their healthcare
provisions, which are more relevant in RLS. In addition,
clinic-based pill counts could not predict virologic out-
come. Generally, clinic-based pill counts performed poorly
in other studies, also [42]. Unannounced pill counts
conducted in homes have been closely associated with
virological suppression [7,43], the development of HIVDR
[7], and progression to AIDS [44], but are less feasible.
This study found no association between appointment
keeping and viral load. Authors who found a better correl-
ation [45] suggested that monitoring of clinic attendance
may be an objective and effective measure, and could
be a useful adjunct to an adherence measure, such as
pill counting in RLS. Human resource constraints in these
settings do not allow pill counts or other time-consuming
measures to be taken. Therefore, monitoring clinic attend-
ance and acting on missed appointments may be an effect-
ive proxy measure [45].
Furthermore, in a Cox regression model, after accounting
for age, gender, and immunological status, the groups of pa-
tients having pharmacy refill > 95% were more likely to re-
cover immunologically in a relatively-shorter period than
the non-adherent group. The cross validation after fitting
the adherence in logistic regression indicate that adherence
estimates combined with other variables performs bet-
ter in predicting the virological outcome than adherence
alone. These results indicated that a model combining only
adherence and immunological response performs equally
well, even better than using adherence alone. This model is
important in routine clinical practice because immuno-
logical outcome is easily available, whereas other variables
may not be so easily and routinely available to use for
predicting therapy response.
The study findings are limited by a small sample size
obtained by convenient sampling of individuals who
were initiating or continuing ART within the three months
period of recruitment at the study site.
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Of the adherence methods investigated in this study,
pharmacy refill method had the best performance in pre-
dicting virological failure. The performance improved
when pharmacy refill adherence was combined with im-
munological response. The study found, this combination
to have a reasonable sensitivity (around 70%) and specificity
(around 60%) to predict virological failure. This combin-
ation could be useful to flag patients at risk for virological
failure. It appeared to be more reliable than immunological
and clinical response alone and was cost-saving. Thus, it
had the potential for a wider application in ART follow-up
in RLS. When combined with even more variables, such as
treatment and demographic characteristics in the full logis-
tic regression model, the prediction still improved, however
this may become less straightforward and may, thus, lose
applicability in RLS where doctors have very little time to
devote to individual patients.
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